Reviewed Mar 2026 | PubMed sources
Active Market
United Kingdom is selected. The evidence comparison is still valid, but provider availability, legal positioning, and cost assumptions may still be staged for later rollout.

Semaglutide vs Retatrutide: Head-to-Head Comparison

Semaglutide is the most widely prescribed GLP-1 agonist with proven CV benefits and ~15% weight loss. Retatrutide is an investigational triple agonist showing 24.2% weight loss in Phase 2 — potentially the most effective obesity treatment ever tested. Semaglutide is available now; retatrutide remains in clinical trials.

Approved Comparison Routing

Approved options in this comparison

A
Semaglutide

Semaglutide is currently modeled on this site as an approved treatment path for: Type 2 diabetes mellitus; chronic weight management in adults with obesity or overweight with comorbidities. Brand names in the current dataset: Ozempic, Wegovy, Rybelsus.

Validation note: This block reflects the site's current structured treatment data and internal routing logic. It does not replace checking current labeling, payer rules, or local prescribing conditions.

Want to discuss Semaglutide with a provider?

Semaglutide is currently modeled on this site as an approved treatment path. Use the provider matcher to narrow fit by state, insurance, budget, and urgency.

Join provider rollout

Semaglutide Next Steps

UK selected - using US-first conversion assets

Side-by-Side Comparison

DimensionSemaglutideRetatrutide
Evidence LevelLevel A — extensive Phase 3 data and real-world evidenceLevel B — Phase 2 RCT; Phase 3 ongoing (TRIUMPH)
FDA StatusApproved for T2D and obesity (multiple formulations)Not approved; still in Phase 3 clinical trials
Weight Loss Efficacy~15% mean body weight loss (Wegovy 2.4 mg)Up to 24.2% weight loss (12 mg dose, Phase 2)
MechanismGLP-1 receptor agonist onlyTriple agonist: GIP + GLP-1 + glucagon receptors
Side EffectsWell-characterized GI side effects; manageableSimilar GI profile; long-term safety unknown
Cardiovascular DataProven 20% CV event reduction (SELECT trial)No CV outcome data yet
Evidence Level
Semaglutide
Level A — extensive Phase 3 data and real-world evidence
Retatrutide
Level B — Phase 2 RCT; Phase 3 ongoing (TRIUMPH)
FDA Status
Semaglutide
Approved for T2D and obesity (multiple formulations)
Retatrutide
Not approved; still in Phase 3 clinical trials
Weight Loss Efficacy
Semaglutide
~15% mean body weight loss (Wegovy 2.4 mg)
Retatrutide
Up to 24.2% weight loss (12 mg dose, Phase 2)
Mechanism
Semaglutide
GLP-1 receptor agonist only
Retatrutide
Triple agonist: GIP + GLP-1 + glucagon receptors
Side Effects
Semaglutide
Well-characterized GI side effects; manageable
Retatrutide
Similar GI profile; long-term safety unknown
Cardiovascular Data
Semaglutide
Proven 20% CV event reduction (SELECT trial)
Retatrutide
No CV outcome data yet

Peptide Overviews

Semaglutide

AFDA Approved

Semaglutide is a GLP-1 receptor agonist approved by the FDA for type 2 diabetes (Ozempic, Rybelsus) and chronic weight management (Wegovy). One of the most studied peptide drugs in recent history.

Weight LossFDA Approved
View full Semaglutide profile →

Retatrutide

BHuman Studies

Retatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly. It simultaneously targets GIP, GLP-1, and glucagon receptors, achieving the highest weight loss ever reported in an obesity clinical trial — up to 24.2% at 48 weeks.

Weight LossNot Approved
View full Retatrutide profile →

GLP-1 Support Essentials

Products that can support side-effect management, hydration, and protein intake.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Supplies for Both

Common research handling and preparation supplies for injectable peptide workflows.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Recommended Reading

Books covering peptide science, longevity research, and biohacking frameworks.

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Semaglutide vs Retatrutide: FAQ